Unaudited financial results(provisional) for the quarter ended 30th sept, 2006
PARTICULARS
3 months
6 months
Year ended
30.09.2006
30.09.2005
31.03.2006
Unaudited
Audited
Net Sales/Operational Income
7287.73
8027.62
12584.60
16025.07
32341.62
Others Income
164.45
45.19
434.91
63.96
103.41
TOTAL EXPENDITURE :
6068.94
6538.64
10349.73
13060.04
26300.61
(a) (Increase)/decrease in stock in trade
(316.71)
(753.15)
(728.15)
(842.30)
(1595.27)
(b) Consumption of Raw Material
4740.63
5810.18
7762.09
11188.30
22070.92
(c) Staff Cost
200.65
155.04
393.47
290.00
640.02
(d) Other expenditure
1444.37
1326.57
2922.32
2424.03
5184.93
Interest
536.92
280.28
1024.65
515.62
1245.20
Depreciation
283.51
202.89
573.27
349.72
810.88
Profit before tax
562.81
1051.01
1071.86
2163.65
4088.34
Provision for taxation
73.52
88.53
135.64
182.07
361.14
Provision for Fringe Benefit Tax
4.07
2.00
5.45
3.00
6.38
Net Profit before Deferred Tax
485.21
960.48
930.77
1978.58
3720.82
Provision for deferred tax
35.00
133.47
57.16
147.14
242.14
Net Profit
450.21
827.01
873.61
1831.44
3478.68
Paid up Equity Share Capital
2212.00
2090.00
2152.00
Reserve excluding revaluation reserves
18370.69
15080.58
16810.23
EPS Rs. (Not Annualised) Basic
2.05
4.44
3.98
9.83
17.52
Diluted
4.24
9.40
17.00
Aggregate of Non-Promoters Shareholding
No. of Shares
15704594
15504594
% of Shareholding
71.00%
74.18%
72.05%
1
The decrease in turnover is due to decrease in the domestic sales. The Exports have however registered an increase of 21.04% during the quarter.
2
Information on Investor Complaints for the quarter : Opening Balance Nil, Received 4, Redressed 4, closing Balance Nil.
3
The previous period figures have been re-grouped and re-arranged wherever necessary.
4
The Company is exclusively in the Pharmaceutical business segment.
5
The above results were taken on record by the Board of Directors in its meeting held on 28 th October, 2006.
